Comparison of NNRTIs in antiretroviral-naïve patients

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, [http://www.hivatis.org (accessed 28 January 2000)]

British HIV Association (BHIVA) Guidelines for the Treatment of HIV. New BHIVA Guidelines. Issued December 1999. [http://www.aidsmap.com/bhiva/bhivagdl299.htm (accessed 14 December 2000)]

Arribas J , Staszewski S , Nelson M Three-year durability of response with an efavirenz (EFV)-containing regimen: 144-week follow-up from Study 006. 11th European Congress of Clinical Microbiology and Infectious Diseases. Istanbul, Turkey, April 2001. Abstract 043

Tashima K , Staszewski S , Morales-Ramirez JO Efavirenz (EFV)+zidovudine (ZDV)+lamivudine (3TC) provides superior long-term HIV-RNA suppression, antiretroviral activity and tolerability versus indinavir (IDV)+ZDV+3TC: results of Study 006 at 72 weeks (initial cohort). 37th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, USA, November 1999. Abstract 366

Luskin-Hawk R , Cohen C , Lang J Efavirenz is well tolerated and highly efficacious in combination with the nucleosides stavudine (d4T)+didanosine (ddI) or d4T+la-mivudine (3TC). 37th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, USA, November 1999. Abstract 349

Cohen C , Elion R , Green S Sustiva™ (efavirenz) is highly effective and well tolerated in combination with the nucleosides stavudine and lamivudine (Study DMP 266-043). 40th Inter seience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000. Abstract 538

Riddler S , Kahn J , Martin G Durable HIV suppression and tolerability with efavirenz (EFV)+indinavir (IDV): results at 132 weeks (Study 033-Cohort IV). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, January-February 2000. Abstract 513

Squires K , Johnson V , Katlama C The Atlantic Study: a randomised, open-label study to evaluate the efficacy and safety of three triple-combination therapies aimed at different HIV targets in antiretroviral naïve HIV-1 infected patients. 13th International AIDS Conference. Durban, South Africa, July 2000. Abstract LbPeB7046

Podzamczer D , Ferrer E , Consiglio E A randomized, open, multicenter trial comparing Combivir plus nelfinavir or nevirapine in HIV-infected naïve patients (The Combine Study). 40th Inter science Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000. Abstract 694

Johnson M , Beall G , Badley A ABT-378/ritonavir (ABT-378/r) versus nelfinavir in antiretroviral naïve subjects: week 48 comparison in a phase III blinded randomized clinical trial. AIDS 2000;14 (Suppl 4):S7, Abstract PL6.5

Montaner JSG , Reiss P , Cooper D A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial. JAMA 1998;279:9307

Pollard R and the 1090 Team. Factors predictive of durable HIV suppression in a randomized double blind trial with nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) in treatment-naive (ARV-n) patients with advanced AIDS. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, January-February 2000. Abstract 517

Phillips AN , Pradler C , Lazzarin A Virological and clinical outcome of NNRTI-containing regime patients in EuroSIDA. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 2001. Abstract 324

Raffi F , Reliquet V , Ferre V d4T+qd ddl+nevirapine (bid or qd) in antiretroviral-naïve HIV-1 infected patients: 1-year results of the VIRGO study. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA, September 1999. Abstract 1978

Russell DB , Bal J , Anderson JSIC , Moore R . The efficacy of nevirapine at low versus high viral loads. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection. Lisbon, Portugal, October 1999. Abstract 518

Raffi F , Reliquet V . Nevirapine (NVP) shown to be equally effective at both high and low viral loads. 13th International AIDS Conference. Durban, South Africa, July 2000. Abstract TuPpB1168

Raboud J , Montaner JSG , Rae S Patients with higher baseline pVL are less likely to have a virologie response in a meta-analysis of two trials of ZDV/ddI vs ZDV/ddl/NVP. 12th World AIDS Conference. Geneva, Switzerland, June-July 1998. Abstract 12361

Nelson MR , Shaw A , Baker R , Bower M , Fisher M , Gazzard BG . Response of individuals with high viral load to non-nucleoside reverse transcriptase inhibitors. 6th Annual Conference of the British HIV Association. Edinburgh, UK, March 2000. Abstract P17

Nelson M , Staszewski S , Morales-Ramirez JO Successful virologie suppression with efavirenz in HIV-infected patients with low baseline CD4 cell counts: post-hoc results from Study 006.10th European Congress of Clinical Microbiology and Infectious Diseases. Stockholm, Sweden, May 2000. Abstract 3-349

Baker RW , Gazzard BG , Nelson MR . Comparison of combination antiretroviral chemotherapy in patients with low initial CD4 counts. 6th Annual Conference of the British HIV Association. Edinburgh, UK, March 2000. Abstract 18

Jones B , Jarvis P , Lewis JA , Ebbutt AF . Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:369